Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season

A short course of 5 injection AIT with Bet v 1 Contiguous Overlapping Peptides was well tolerated and improved allergic rhinitis during the 2nd pollen season after treatment. Long lasting efficacy was associated with a persistent allergen-specific IgG4 response.

Source: Journal of Allergy and Clinical Immunology - April 17, 2018 Category: Allergy & Immunology Authors: Alexander Kettner, Gilles DellaCorte, Fr éderic de Blay, Lars Jacobsen, Marek Jutel, Margitta Worm, Vincent Charlon, Kim Simonsen, Christophe Reymond, François Spertini Source Type: research